May 2026 - Page 10 of 22

ThursdayMay 14, 2026 11:44 am

QualityStocksNewsBreaks – American Fusion Inc. (OTC: AMFN) Highlights Strategic Washington Engagements, Provides Corporate Update

American Fusion (OTC: AMFN) provided an update on recent strategic engagements in Washington, D.C., where the company discussed potential applications for its Texatron(TM) Fusion Engine(TM) platform across defense, infrastructure and national energy resilience initiatives. The company also outlined corporate progress, including anticipated Form 10 effectiveness, advancement of its Rule 15c2-11 quotation application, pursuit of OTCQB qualification and continued development of its 5MW Texatron pre-production unit as it advances commercialization and capital markets objectives. To view the full press release, visit https://ibn.fm/hevBS About American Fusion Inc. American Fusion Inc. (OTC: AMFN) is an advanced energy platform company focused on the development and commercialization of next-generation fusion energy technologies. The Company is advancing…

ThursdayMay 14, 2026 11:35 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation

Oncotelic Therapeutics (OTCQB: OTLC) announced its featured placement in a BioMedWire editorial focused on emerging CNS drug delivery technologies addressing challenges in Alzheimer’s disease and biodefense research. The editorial highlights the company’s proprietary intranasal nose-to-brain delivery platform, designed to bypass the blood-brain barrier and enable direct therapeutic delivery to the central nervous system, reflecting growing interest in advanced drug delivery approaches for neurological treatment. To view the full press release, visit https://ibn.fm/wgFw3 About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage…

ThursdayMay 14, 2026 11:27 am

QualityStocksNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Emerging GLP-1 Innovation

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) announced its featured placement in a BioMedWire editorial examining next-generation innovation in the rapidly expanding GLP-1 therapeutic market. The editorial highlights the company’s subsidiary GlucaPharm Inc. and its development of GEP-44, a novel triple agonist peptide designed to enhance efficacy, tolerability and delivery flexibility in the treatment of obesity, type 2 diabetes and related metabolic conditions. To view the full press release, visit https://ibn.fm/X8Dwj About SureNano Science Ltd. SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing…

ThursdayMay 14, 2026 11:15 am

QualityStocksNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Shareholders Approve All Proposals at Annual Meeting

This article has been disseminated on behalf of Trilogy Metals Inc. and may include paid advertising. Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) announced that shareholders approved all proposals at its annual meeting held May 13, 2026, with 108.4 million shares, representing 62.84% of eligible outstanding shares, represented at the meeting. Shareholders elected all nominated directors, approved the appointment of auditors, and passed the company’s non-binding advisory vote on executive compensation. To view the full press release, visit https://ibn.fm/6e2DP About Trilogy Metals Trilogy Metals Inc. is a metal exploration and development company holding a 50 percent interest in Ambler Metals LLC, which has a 100 percent interest in the Upper Kobuk…

ThursdayMay 14, 2026 10:10 am

QualityStocksNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Featured in AINewsWire Editorial on Autonomous Warfare Technologies

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) announced its featured placement in an editorial published by AINewsWire examining the evolving role of autonomous software in modern warfare. The editorial highlights SPARC AI’s software-only platform designed to provide drones with GPS-denied navigation and precision targeting capabilities, addressing growing defense demand for autonomous intelligence systems that can operate effectively in contested electronic warfare environments. To view the full press release, visit https://ibn.fm/keot1 About SPARC AI Inc. SPARC AI is a defence technology company solving one…

ThursdayMay 14, 2026 10:00 am

QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in BioMedWire Editorial on Real-Time Intoxication Detection Technologies

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced its featured placement in an editorial published by BioMedWire, highlighting emerging opportunities in real-time intoxication detection technologies. The editorial spotlights MindBio’s AI-driven voice analysis platform, which is being developed to detect impairment from brief speech recordings across a range of substances, addressing growing demand for faster, noninvasive and scalable intoxication detection solutions across healthcare, workplace safety and public health applications. To view the full press release, visit https://ibn.fm/1WCqA About MindBio Therapeutics Corp. MindBio is a…

ThursdayMay 14, 2026 9:50 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic transformation toward an acquisition-driven growth model focused on clinical-stage neurology and oncology assets. Following quarter end, the company strengthened its balance sheet with a $22.5 million private placement, which, together with existing cash, is expected to support operations beyond 12 months as CNS pursues asset acquisitions and explores out-licensing opportunities for its legacy glioblastoma programs. To view the full press release, visit https://ibn.fm/HP5Xy About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive…

ThursdayMay 14, 2026 9:45 am

BluSky AI Inc. (BSAI) Outlines Scalable SkyMod Architecture as AI Infrastructure Demand Accelerates

BluSky AI’s business plan includes the rapid deployment of SkyMod data centers intended to address rising demand for high-performance AI infrastructure. The company’s strategy reflects a broader mission to expand access to AI computing through flexible, efficient, and fast-to-deploy modular systems. The global demand for compute, energy, specialized chips, and data center infrastructure continues to grow at a pace that challenges traditional development timelines. What was once a steady progression in hardware and software has evolved into a race to maintain capacity, where organizations increasingly recognize that physical infrastructure is a critical limiting factor. Industry commentary has underscored this shift.…

ThursdayMay 14, 2026 9:36 am

QualityStocksNewsBreaks – BOXABL, FG Merger II Advance Proposed Business Combination Following SEC Effectiveness of Form S-4

BOXABL and FG Merger II Corp. (NASDAQ: FGMC) announced that the U.S. Securities and Exchange Commission has declared effective the companies’ joint registration statement on Form S-4 related to their proposed business combination, marking a significant milestone in BOXABL’s path to becoming a publicly traded company. Shareholder meetings to approve the transaction are scheduled for June 9, 2026, with closing expected shortly thereafter, subject to customary conditions, after which the combined company is expected to trade on Nasdaq under the ticker symbol BXBL. To view the full press release, visit https://ibn.fm/1jXwV About BOXABL BOXABL is transforming the housing market with its modular building systems…

ThursdayMay 14, 2026 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives. To view the full press release, visit https://ibn.fm/guMCF About HeartBeam, Inc. HeartBeam,…

Site Search

Company Search

Month: May 2026